Skip to content

Transient Elastography (FibroTouch) for Assessing Risk of Gastroesophageal Varices Bleeding in Compensated Cirrhosis (Pan-CHESS1801)

Transient Elastography (FibroTouch) for Assessing Risk of Gastroesophageal Varices Bleeding in Patients With Compensated Cirrhosis (Pan-CHESS1801): An International Multicenter Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03778775
Enrollment
200
Registered
2018-12-19
Start date
2018-12-14
Completion date
2022-03-13
Last updated
2021-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compensated Liver Cirrhosis, Gastroesophageal Varices Bleeding

Keywords

Transient elastography, Gastroesophageal varices bleeding, Varices needing treatment

Brief summary

Gastroesophageal varices occurs in approximately half of the patients with liver cirrhosis. Variceal bleeding is the most common lethal complication directly from cirrhotic portal hypertension. The golden standard for diagnosing gastroesophageal varices and evaluating the risk of variceal bleeding is the esophagogastroduodenoscopy. According to the Baveno VI consensus, for those with high-risk varices (varies needing treatment), either non-selective beta blockers or endoscopic band ligation is recommended for the prevention of the first variceal bleeding. However, the invasiveness and uncomfortableness during the esophagogastroduodenoscopy procedure has hindered its routine use in clinical practice, especially in compensated cirrhotic patients. The important role of transient elastography for defining the presence of high-risk varices was highlighted in the Baveno VI consensus workshop that cirrhotic patients with a liver stiffness measurement (LSM) of less than 20 kPa and a platelet count of greater than 150,000/μL can avoid screening endoscopy. In addition, transient elastography-based models (e.g. LSM combined with platelet count, liver stiffness spleen diameter-to-platelet score) were shown to have potentials in distinguish the absence of high-risk gastroesophageal varices. However, this cutoff value of LSM was validated mainly in cohorts with alcoholic or hepatitis C virus dominated cirrhosis. The unmet need is a precise cutoff to rule out high-risk varices in hepatitis B virus dominated cirrhosis, which is an outstanding issue in Asia-Pacific population. FibroTouch (Hisky Medical Technologies Co. Ltd, Wuxi, China) is a new-generation of transient elastography based on a two-dimensional image-guided system to ensure the precise orientation. In the present study, the investigators aim to conduct an international prospective diagnostic trial with 16 sites to develop and validate the diagnostic performance of FibroTouch-based models for assessing risk of gastroesophageal varices bleeding in compensated cirrhosis.

Detailed description

Gastroesophageal varices occurs in approximately half of the patients with liver cirrhosis. Variceal bleeding is the most common lethal complication directly from cirrhotic portal hypertension. The golden standard for diagnosing gastroesophageal varices and evaluating the risk of variceal bleeding is the esophagogastroduodenoscopy. According to the Baveno VI consensus, for those with high-risk varices (varies needing treatment), either non-selective beta blockers or endoscopic band ligation is recommended for the prevention of the first variceal bleeding. However, the invasiveness and uncomfortableness during the esophagogastroduodenoscopy procedure has hindered its routine use in clinical practice, especially in compensated cirrhotic patients. The important role of transient elastography for defining the presence of high-risk varices was highlighted in the Baveno VI consensus workshop that cirrhotic patients with a liver stiffness measurement (LSM) of less than 20 kPa and a platelet count of greater than 150,000/μL can avoid screening endoscopy. In addition, transient elastography-based models (e.g. LSM combined with platelet count, liver stiffness spleen diameter-to-platelet score) were shown to have potentials in distinguish the absence of high-risk gastroesophageal varices. However, this cutoff value of LSM was validated mainly in cohorts with alcoholic or hepatitis C virus dominated cirrhosis. The unmet need is a precise cutoff to rule out high-risk varices in hepatitis B virus dominated cirrhosis, which is an outstanding issue in Asia-Pacific population. FibroTouch (Hisky Medical Technologies Co. Ltd, Wuxi, China) is a new-generation of transient elastography based on a two-dimensional image-guided system to ensure the precise orientation. In the present study, the investigators aim to conduct an international prospective diagnostic trial with 16 sites (Beijing Tsinghua Changgung Hospital, Lanzhou University, The Fifth Medical Center of Chinese PLA General Hospital, Xijing Hospital of Digestive Diseases Wuhan Union Hospital, Zhujiang Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, The Central Hospital of Lishui City, Xingtai People's Hospital, The Seventh Medical Center of Chinese PLA General Hospital Shandong Provincial Hospital, Shunde Hospital, Southern Medical University Medistra Hospital; University of Indonesia, Ankara University School of Medicine, Osaka City University, Chulalongkorn University) to develop and validate the diagnostic performance of FibroTouch-based models for assessing risk of gastroesophageal varices bleeding in compensated cirrhosis.

Interventions

DIAGNOSTIC_TESTLiver sitffness measurement

Liver sitffness measurement is performed by FibroTouch, a new-generation of transient elastography with the tesing interval between liver sitffness measurement and esophagogastroduodenoscopy less than one week.

Sponsors

Beijing Tsinghua Changgeng Hospital
CollaboratorOTHER
LanZhou University
CollaboratorOTHER
Beijing 302 Hospital
CollaboratorOTHER
Xijing Hospital of Digestive Diseases
CollaboratorOTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CollaboratorOTHER
Zhujiang Hospital
CollaboratorOTHER
Second Affiliated Hospital of Xi'an Jiaotong University
CollaboratorOTHER
The Central Hospital of Lishui City
CollaboratorOTHER
Xingtai People's Hospital
CollaboratorOTHER
Seventh Medical Center of PLA Army General Hospital
CollaboratorOTHER
Shandong Provincial Hospital
CollaboratorOTHER_GOV
Southern Medical University, China
CollaboratorOTHER
Medistra Hospital, University of Indonesia
CollaboratorUNKNOWN
Ankara University
CollaboratorOTHER
Osaka City University
CollaboratorOTHER
Chulalongkorn University
CollaboratorOTHER
Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* age 18-75 years; * confirmed liver cirrhosis based on liver biopsy or clinical findings; * compensated liver cirrhosis; * scheduled to undergo esophagogastroduodenoscopy; * estimated survival time\> 24 months, and model for end-stage liver disease (MELD) score\< 19; * with written informed consent.

Exclusion criteria

* contradictions for esophagogastroduodenoscopy; * body mass index\> 35 kg/m2; * presence of decompensation events (e.g. ascites, variceal bleeding, hepatic encephalopathy, etc.); * previous esophageal variceal banding legation or transjugular intrahepatic portosystemic shunt; * current use of non-selective beta-blockers; * with portal vein thrombosis or hepatocellular carcinoma; * non-cirrhotic portal hypertension; * pregnancy or unknown pregnancy status.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic accuracy of FibroTouch-based models for the risk of variceal bleeding1 dayDiagnostic accuracy of FibroTouch-based models to determine the high-risk or low-risk of variceal bleeding with esophagogastroduodenoscopy as the reference standard

Secondary

MeasureTime frameDescription
The correlation between FibroTouch-based models and HVPG1 dayThe correlation between FibroTouch-based models and hepatic venous pressure gradient (HVPG)
Diagnostic accuracy of FibroTouch-based models for the decompensated events of cirrhotic portal hypertension1 yearDiagnostic accuracy of FibroTouch-based models to determine the presence or absence of decompensated events (e.g. first variceal bleeding) within 1-year follow-up

Countries

China, Indonesia, Japan, Thailand, Turkey (Türkiye)

Contacts

Primary ContactXiaolong Qi, MD
qixiaolong@vip.163.com18588602600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026